American Society of Hirudotherapy

LDTI-2 (Leech-Derived Trypsin Inhibitor, Variant 2)

Sequence variant of LDTI — selective tryptase / trypsin inhibitor relevant to mast-cell pathways.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • LDTI-2 (Leech-Derived Trypsin Inhibitor, Variant 2)4.8 kDa
Molecular weight (kilodaltons) of LDTI-2 (Leech-Derived Trypsin Inhibitor, Variant 2) (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound

Clinical translation limit

LDTI-2 is documented mechanistically only; no human evidence. In vitro inhibition of tryptase/trypsin does NOT establish clinical efficacy in mast-cell-mediated disease, and no FDA-approved derivative exists.

Molecular Profile

Category
Proteinase Inhibitor
Evidence tier
Preclinical
Molecular weight
4,800 Da
Source species
Hirudo medicinalis
Discovered
2010

Biological Targets

  • → tryptase
  • → trypsin

Key Citations

  1. Liu Z et al. (2019), Parasit Vectors

External Resources

    Related Proteinase Inhibitor Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.